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An H5N1 influenza DNA vaccine for South Africa
The highly pathogenic avian influenza virus H5N1 is a potent pandemic threat because of its frequent 
transmission from birds to humans and the increasing possibility of human to human transmission. During 
the 2009 H1N1 pandemic it was clear that rapid influenza vaccine production is a problem worldwide. 
Additionally, developing countries like South Africa generally cannot produce their own influenza vaccines 
because the traditional egg-based vaccine production method currently employed is too lengthy and too 
difficult to establish. As part of an exercise aimed at exploring the feasibility of producing emergency 
response influenza vaccines, we investigated an experimental DNA vaccine to the H5N1 influenza virus. We 
focused on the virion haemagglutinin, because it elicits the primary neutralising immune response following 
infection. Accordingly, we developed an H5N1 DNA vaccine with full-length and truncated versions of the 
haemagglutinin gene, to match previously developed protein candidates. Vaccinated mice developed a 
strong antibody response to the haemagglutinin protein. In addition, the full-length H5 gene elicited high 
haemagglutination inhibition titres in mice, indicating that it has potential as a candidate pandemic vaccine 
for South Africa. 
Introduction
There have been five influenza pandemics over the last 125 years, with the Spanish flu in 1918 being the most 
notorious. The most recent (‘swine flu’) pandemic in 2009 was caused by influenza A H1N1, which originated in 
Mexico and rapidly spread globally, resulting in over 18 000 deaths.1 During this pandemic it became clear that 
South Africa does not have the ability to produce influenza vaccines, that we would be reliant on vaccine stocks 
from developed countries, and that these might be slow in coming. 
The highly pathogenic avian influenza virus (HPAIV) subtype H5N1 has significant potential for causing a future 
pandemic, as a result of its frequent transmission from birds to mammals and continued persistence in several 
countries.2 There have been over 250 cases reported in humans, with deaths occurring in 60% of infected 
individuals. There is also the possibility of mutation and/or re-assortment of the virus to create a strain capable of 
enabling efficient human to human transmission; therefore, it is necessary to ensure that countries are equipped to 
handle a pandemic via an efficient vaccination approach.3
Current influenza vaccine production involves the use of mainly chicken egg produced trivalent inactivated vaccine. 
This system can take 4–6 months to produce a vaccine, and is demonstrably not capable of coping with the 
demand for vaccines in the event of a pandemic. Additionally, H5N1 is highly pathogenic to chickens, which has 
a negative effect on egg production levels.4 DNA vaccines, in contrast, can be produced in as short a time as 
3 weeks.5,6 These vaccines have several advantages over the use of conventional inactivated vaccines as they 
can rapidly elicit both humoral and cell-mediated immune responses, and are non-infectious. DNA vaccines are 
heat stable and can initiate cell-mediated immune responses without the need for adjuvants.7 They are easy to 
construct, allowing for rapid large-scale production to meet demand in case of a pandemic.8 The potential of H5N1 
DNA vaccines to protect against lethal viral challenges has also been demonstrated in animal models.9
South Africa, like other African countries, unfortunately does not have the facilities to produce conventional 
egg-based vaccines. When faced with the 2009 ‘swine flu’ influenza A H1N1 pandemic, the country had to rely 
on the World Health Organization and developed countries for vaccine stocks.10 The 2009 H1N1 pandemic did not 
represent a great threat for healthy people; however, serious complications were reported for immunocompromised 
people. As South Africa has the highest number of human immunodeficiency virus (HIV) cases in the world,11 it 
is important to have an influenza pandemic contingency plan in place for when the next pandemic occurs. Ideally, 
developing countries like South Africa should be able to produce their own pandemic vaccine as quickly as possible. 
Accordingly, and as part of an effort to establish the feasibility of pandemic influenza response capability, in this 
paper we describe the development and testing in mice of a candidate H5 HA gene DNA vaccine in South Africa. 
Materials and methods
Construction of haemagglutinin DNA vaccines
The full-length haemagglutinin (HA) gene (H5; 1704 bp) and a truncated form (H5tr; 1635 bp) lacking the 23-amino 
acid anchoring membrane domain (nucleotides 1597–1665 bp) of the A/Vietnam/1194/2004 strain (H5N1, 
GenBank accession number AY651333) were human-codon optimised and synthesised by GeneArt® (Regensburg, 
Germany) and called pPCR-Script_H5 and pPCR-Script_H5tr. The membrane-anchoring domain was removed from 
H5tr to prevent membrane insertion of the haemagglutinin. The protein produced was thus soluble, which increased 
production levels. The 5’ ends of the HA genes were modified by means of oligonucleotide linkers by adding a 
Hind III restriction enzyme site and a Kozak sequence (GCCACCATGG); a BamHI site was added to the 3’ end. The 
high-performance liquid chromatography purified oligonucleotides H5KozakF 5’ CGGATCCAAGCTTACGCGTGCCAC 
3’ and H5KozakR 5’ GTA CCACCGTGCGCATTCGAACCTAGGCCATG 3’ were annealed to form a 5’ end linker, while 
H5 3’F 5’ GGCCGCATAATCTAGAGGATCCGAGCT 3’ and H5 3’R 5’ CGGATCCTCTAGATTAT GC 3’ were annealed 
to form the 3’ end linker. The GeneArt-provided plasmid DNAs were digested, linkers were ligated and genes were 
cloned into pUC 18, before sequencing with the M13F and M13R universal primers. The modified HA genes were 
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has the human cytomegalovirus enhancer and the intron A region, which 
resulted in high levels of vaccine protein production for a number of 
candidates, including HIV-1 subtype C.13
Expression of haemagglutinin DNA vaccines
Endotoxin-free DNA was prepared for both pTH_H5 and pTH_H5tr using 
a commercial Giga kit (Qiagen, Hilden, Germany). HA protein expression 
from the two constructs was verified by western blot analysis of 
transfected HEK 293 cells. The cells were cultured in complete medium 
containing Dulbecco’s modified Eagle’s medium (Invitrogen) with 10% 
foetal calf serum, 1% penicillin/streptomycin and 10 µg/mL Fungin in 
T75 flasks and incubated in a 5% CO2 tissue culture 37 °C incubator 
until 80–90% confluency was reached. Prior to transfection, the HEK 
293 cells were diluted to 0.5x106 cells and plated out in 35-mm 6-well 
plates. Transfection reagent (FuGENE® 6, Roche, Mannheim, Germany) 
was used at the recommended different reagent to DNA ratios, namely 
3:1, 3:2 and 6:1. Each ratio was performed in duplicate for pTH_H5 and 
pTH_H5tr as well as for a negative cell control, a FuGENE® 6 only control 
(i.e. no DNA) and a DNA only control (i.e. no transfection reagent). After 
72 h, the HEK cells were harvested with cold Dulbecco’s phosphate 
buffered saline (PBS, Sigma) and were lysed with 1 x chloramphenicol 
acetyltransferase lysis buffer (Roche). 
Lysed cell samples and supernatant were assayed for protein expression 
by loading the sample on a 10% SDS-polyacrylamide (PAGE) gel. The 
transfer of proteins from gels to nitrocellulose membranes was done 
by means of semi-dry electroblotting (Bio-Rad). Rabbit anti-H5N1 
polyclonal antibody (US Biological, GenBank accession number 
AAT6166) was used at a 1:1000 dilution together with a secondary 
alkaline phosphatase-labelled goat anti-rabbit antibody (Sigma) at a 
1:7000 dilution. NBT/BCIP solution (Roche) was used for detection. 
We determined that the optimum transfectant to DNA ratios for H5 and 
H5tr were 6:1 and 3:1, respectively. This transfection experiment was 
repeated twice to confirm results.
Mouse immunisation
A total of 30 healthy 7-week-old female Balb/c mice were equally divided 
into three groups. Each group received one of the following: (1) pTH_H5 
DNA vaccine, (2) pTH_H5tr DNA vaccine or (3) PBS (a negative control 
group). A total dose of 100 µg pTH_H5 and pTH_H5tr endotoxin-free DNA 
in 100 µL was administered intramuscularly to mice – 50 µL into each 
anterior tibialis muscle – after mice received an intraperitoneal anaesthetic 
mixture of ketamine (120 mg/kg) and xylazine (16 mg/kg, Rompun®). 
Four doses were administered at 2-week intervals. The mice were pre-
bled (100 µL) 3 days before vaccination was initiated. Final blood samples 
were taken 2 weeks after the fourth vaccine dose. The animal experiments 
were approved by the University of Cape Town’s Animal Ethics Committee 
(HSFAEC 009001). At the end of the experiment, sera were collected and 
stored at -20 °C for further processing.
Serological assays
Western blots were performed on in-house plant-produced H5 and H5tr 
protein samples (A/Vietnam/1194/2004)14 separated on 10% SDS-PAGE 
gels. Following semi-dry blotting, membranes were cut into individual 
strips and incubated in 1:200 dilutions of sera from immunised mice. A 
positive control was also included that used the primary antibody (rabbit 
anti-H5N1 polyclonal antibody, US Biologicals, Swampscott, MA, USA) 
at a 1:500 dilution followed by the secondary goat anti-rabbit antibody 
(Sigma-Aldrich, Johannesburg, South Africa). 
Haemagglutination inhibition (HI) tests were performed at the National 
Institute for Communicable Diseases (NICD, Johannesburg, South 
Africa). The mice sera were treated with a receptor destroying enzyme 
(RDE II, Denka Seiken) to a dilution of 1:10 (1 part serum + 3 parts 
RDE, incubated overnight at 37 °C, heat inactivated at 56 °C for 30 min 
and another 6 volumes of saline added). Following this, serial dilutions 
of the sera were mixed with a standard 4HAU/25-µL dose of Influenza 
A H5N1 antigen received from the Centers for Disease Control and 
Prevention (CDC, Atlanta, GA, USA). Following incubation, a 0.5% 
suspension of turkey red blood cells was used as an indicator system 
to assess inhibition of haemagglutination. Influenza A (H3N2) and 
Influenza A (H1N1) antigens (CDC) were used as negative controls to 
check for cross-reaction. To test for significant differences in antibody 
titres between the two treatment groups (pTH_H5 and pTH_H5tr), we 
performed an independent t-test, after confirming the assumption of 
normality with Shapiro-Wilk tests for each group (p>0.05).
Results and discussion
H1N1 and H5N1 influenza viruses are of keen current interest – H1N1 
because of the role it played in the recent influenza pandemic and H5N1 
because of its potential to cause another pandemic.15,16 DNA vaccines 
continue to be an attractive option for vaccine production in the event 
of a pandemic influenza outbreak as a result of their potential for rapid, 
large-scale development. Influenza DNA vaccines have been shown to 
be as effective as live vaccines, which can protect mice against viral 
challenges, and have entered advanced human trials.6,8,17
We explored the possibility of making a HA DNA vaccine in response to 
a future pandemic in southern Africa, using an established DNA vaccine 
vector which has been used in primate and human studies in the UK and 
in human trials in South Africa,13,18,19 and which contained the full-length 
and truncated forms of a H5N1 HA gene. Both HA variants were expressed 
in HEK 293 cell cultures (results not shown). After confirmation of 
expression, mice were subsequently vaccinated with four doses of these 
potential DNA vaccines. Two weeks following the last vaccination, the 
sera were collected. Western blots were used to determine if H5-specific 
antibodies were elicited in the mice sera following immunisation. Sera 
against both the full-length and truncated vaccine candidates bound 
strongly to in-house plant-produced H5 (Figure 1) from the same strain 
(A/Vietnam/1194/2004) as the HA DNA vaccines. As expected, the sera 
of mice inoculated with PBS (negative control) contained no H5-specific 
antibodies. The positive control (Lane 19) appears weaker than the rest 
as the commercial antibody targets 14 amino acids in the middle of the 
HA protein of a strain (AAT76166) different from the one used in this study. 
H5-specific antibodies from the sera of mice vaccinated with pTH_H5 and 
pTH_H5tr appear to be mostly strain specific, even though cross-reaction 
weakly occurs, as indicated by the positive control. Ideally, cross-reaction 
with other influenza strains will make the candidate vaccines more suitable 
for broader influenza strain protection. However, as a pandemic usually 
starts off with a single viral strain, these results are in line with producing 
a candidate pandemic vaccine.
a
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(a): Lanes 1 and 20 contained the PageRuler™ Prestained protein ladder 
(Fermentas, Burlington, Canada), Lanes 2 to 11 contained the strips 
incubated in pTH_H5-immunised mice sera (dilution 1:200), Lanes 12 to 
18 contained strips incubated in negative control sera (dilution 1:200) and 
Lane 19 contained a positive control – plant-produced H5 detected with a 
commercial anti-H5 antibody. 
(b): Lanes 1 to 8 and Lanes 12 to 13 contained the strips incubated in pTH_H5tr-
immunised mice sera (dilution 1:200), Lane 9 contained a positive control – 
plant-produced H5tr detected with a commercial anti-H5 antibody, Lanes 10 
and 11 contained the PageRuler™ Prestained protein ladder, and Lanes 14 to 
16 contained strips incubated in negative control sera (dilution 1:200). 
Note: The strips were aligned manually which might affect overall alignment.
Figure 1: Western blots of pTH_H5 and pTH_H5tr immunised mice. 
H5-specific antibodies (indicated with an arrow) were present 
in the sera of both (a) pTH_H5 and (b) H5tr-immunised mice. 
Plant-produced H5 antigen was loaded in all the lanes in (a) 
while plant-produced H5tr was loaded in all the lanes in (b). 
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The sera were further tested for the ability to inhibit haemagglutination. 
The HI results (Table 1) indicated that sera from all 10 mice vaccinated 
with the full-length HA gene (pTH_H5) had HI titres ranging from 
1:160 to ≥1:2560. These HI titres were therefore considerably greater 
than 1:40, which is deemed to be the benchmark for protection against 
influenza in humans.20,21 In contrast, the truncated vaccine (pTH_H5tr) 
produced lower titres that ranged from 1:20 to 1:320. Thus, 8 of 10 mice 
had HI titres greater than 1:40. The lower HI values could be because 
the truncated HA form cannot be membrane-bound, which probably 
reduces its immunogenicity. Antibody titres were also significantly 
higher (t=3.645; df=18; p=0.002) for pTH_H5 (1120.00±866.56, 
mean±sd) than for pTH_H5tr (116.00±88.84). Thus, the full-length 
HA (H5) DNA candidate vaccine proved to be more immunogenic than 
its truncated counterpart. These findings are in line with our previous 
results when comparing our plant-produced H5 and H5tr subunit 
candidate vaccines.14
Table 1: Summary of the haemagglutination inhibition (HI) results 
obtained from the final sera samples of each individual female 
Balb/c mouse taken 2 weeks after the fourth vaccination
Group (n=10) Mouse HI titre
































It has been shown that HA DNA vaccines can protect when there is 
a high concentration of HI and neutralising antibodies present.22 The 
potential of H5N1 DNA vaccines has been highlighted by studies that 
indicated a reduction of morbidity and mortality of test animals during 
a lethal H5N1 viral challenge; however, DNA vaccines generally elicit 
only weak immune responses in humans.9 An alternative strategy to 
prevent pandemic outbreaks that has been proposed is the use of a 
DNA prime followed by an inactivated vaccine boost, as this regime 
elicits good immune responses, and one could vaccinate people with 
the DNA vaccine before an outbreak as part of seasonal influenza 
vaccination.23 To this end, we have also developed a plant-made H5 
HA subunit vaccine candidate, which elicits good serum responses in 
mice and chickens.14 
The development of a universal influenza vaccine is ideal and has been 
investigated in an attempt to prevent pandemics. Generally the focus is 
on the highly conserved ectodomain of the matrix-2 protein (M2e) of 
influenza subtype A viruses or haemagglutinin’s conserved stalk domain 
(for a review see Pica and Palese24). For example, a DNA vaccine study 
has shown that the fusion of M2e to H1N1 HA DNA or the mixture of 
M2e and HA DNA improved cross-protection against H5N2 in mice, in 
contrast to immunisations with HA and M2e DNA on their own.25 Also, 
to generate a broadly protective DNA swine vaccine, M2e was fused 
to H3 HA (consensus sequence), as well as to a CTL epitope to H3 
HA. The DNA vaccines generated offered complete homologous strain 
protection and some heterologous protection in mice.23 It is therefore 
worth considering, in terms of future work, determining if there is an 
increase in immunogenicity and cross-protection with the addition of 
M2e to our H5 and H5tr HA constructs. We have already investigated 
the plant production of M2e in fusion with another protein; the result 
could also serve as a combination vaccine (E. Mortimer, I.I. Hitzeroth, S. 
Mbewana and E.P. Rybicki, unpublished results).
DNA vaccines can be stockpiled and can be manufactured in a matter 
of weeks: if other HA genes need to be cloned, all the methodologies 
are established, and the vaccine could be ready within weeks of 
notification. By implementing a DNA vaccine platform, South Africa can 
respond rapidly and potentially remain self-sufficient during a potential 
influenza pandemic.
Conclusion
The H5 DNA vaccine we prepared shows excellent potential in mice; 
it produced good humoral responses and elicited a good HI response. 
We believe this work has further helped us to establish a basis for 
‘rapid response’ influenza vaccine production in South Africa in order to 
develop pandemic preparedness.
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